GAMMA Investing LLC Raises Position in Artivion, Inc. (NYSE:AORT)

GAMMA Investing LLC raised its position in shares of Artivion, Inc. (NYSE:AORT - Free Report) by 1,804.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 52,798 shares of the company's stock after buying an additional 50,026 shares during the period. GAMMA Investing LLC owned about 0.13% of Artivion worth $12,980,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of AORT. Smartleaf Asset Management LLC boosted its holdings in Artivion by 236.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company's stock valued at $32,000 after acquiring an additional 786 shares during the period. Arcadia Investment Management Corp MI acquired a new stake in shares of Artivion during the fourth quarter worth about $43,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Artivion in the fourth quarter valued at approximately $64,000. Venturi Wealth Management LLC purchased a new stake in Artivion during the 4th quarter worth approximately $78,000. Finally, KBC Group NV lifted its holdings in Artivion by 80.4% during the 4th quarter. KBC Group NV now owns 2,813 shares of the company's stock worth $80,000 after buying an additional 1,254 shares in the last quarter. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Artivion Stock Up 1.0%

Artivion stock traded up $0.30 during mid-day trading on Monday, hitting $29.25. The company had a trading volume of 107,646 shares, compared to its average volume of 333,612. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. Artivion, Inc. has a 1 year low of $21.97 and a 1 year high of $32.33. The business has a fifty day moving average of $26.04 and a 200 day moving average of $27.45. The stock has a market cap of $1.25 billion, a price-to-earnings ratio of -1,460.25 and a beta of 1.62.

Artivion (NYSE:AORT - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.06). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The company had revenue of $98.98 million during the quarter, compared to analyst estimates of $94.81 million. On average, sell-side analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Insider Activity

In other Artivion news, Director Anthony B. Semedo sold 2,600 shares of Artivion stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $28.47, for a total value of $74,022.00. Following the transaction, the director now directly owns 33,059 shares in the company, valued at approximately $941,189.73. This trade represents a 7.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Jean F. Holloway sold 8,748 shares of the business's stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $29.00, for a total value of $253,692.00. Following the completion of the transaction, the senior vice president now directly owns 178,510 shares in the company, valued at approximately $5,176,790. The trade was a 4.67% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 64,942 shares of company stock valued at $1,704,794. Insiders own 7.60% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on AORT shares. Needham & Company LLC reaffirmed a "buy" rating and set a $32.00 price objective on shares of Artivion in a research report on Tuesday, May 6th. Citizens Jmp upgraded Artivion to a "strong-buy" rating in a report on Tuesday, May 6th. Stifel Nicolaus decreased their price objective on Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a research note on Tuesday, February 25th. Finally, JMP Securities reissued a "market outperform" rating and set a $33.00 price objective on shares of Artivion in a research report on Tuesday, May 6th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Artivion currently has an average rating of "Buy" and a consensus target price of $31.40.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.